The Role of miR-1183: A Potential Suppressor in Hepatocellular Carcinoma via Regulating Splicing Factor SRSF1

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Hepatocellular carcinoma immunotherapy. Annu Rev Med. 2022;73:267–278. doi:10.1146/annurev-med-042220-021121
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qian J, Gu C, Yang Y. Alternative splicing and cancer: a systematic review. Signal Transduction Targeted Therapy. 2021;6(1):78. doi:10.1038/s41392-021-00486-7
   PubMed Web of Science ®Google Scholar
• Howard JM, Sanford JR. The RNAissance family: SR proteins as multifaceted regulators of gene expression. Wiley Interdiscip Rev RNA. 2015;6(1):93–110. doi:10.1002/wrna.1260
   PubMed Web of Science ®Google Scholar
• Shepard PJ, Hertel KJ. The SR protein family. Genome Biol. 2009;10(10):242. doi:10.1186/gb-2009-10-10-242
   PubMed Web of Science ®Google Scholar
• Wan L, Yu W, Shen E, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2019;68(1):118–129. doi:10.1136/gutjnl-2017-314983
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang M, Meng F, et al. A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis. Cell Death Discovery. 2022;8(1):238. doi:10.1038/s41420-022-01039-9
   PubMed Web of Science ®Google Scholar
• Sun J, Jin T, Su W, et al. The long non-coding RNA PFI protects against pulmonary fibrosis by interacting with splicing regulator SRSF1. Cell Death Differ. 2021;28(10):2916–2930. doi:10.1038/s41418-021-00792-1
   PubMed Web of Science ®Google Scholar
• Lv Y, Zhang W, Zhao J, et al. SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduction Targeted Therapy. 2021;6(1):108. doi:10.1038/s41392-021-00495-6
   PubMed Web of Science ®Google Scholar
• Du JX, Luo YH, Zhang SJ, et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J Exp Clin Cancer Res. 2021;40(1):171. doi:10.1186/s13046-021-01978-8
   PubMed Web of Science ®Google Scholar
• Lei S, Zhang B, Huang L, et al. SRSF1 promotes the inclusion of exon 3 of SRA1 and the invasion of hepatocellular carcinoma cells by interacting with exon 3 of SRA1pre-mRNA. Cell Death Discovery. 2021;7(1):117. doi:10.1038/s41420-021-00498-w
   PubMed Web of Science ®Google Scholar
• Ye Y, Yu F, Li Z, Xie Y, Yu X. RNA binding protein serine/arginine splicing factor 1 promotes the proliferation, migration and invasion of hepatocellular carcinoma by interacting with RecQ protein-like 4 mRNA. Bioengineered. 2021;12(1):6144–6154. doi:10.1080/21655979.2021.1972785
   PubMed Web of Science ®Google Scholar
• Komoll RM, Hu Q, Olarewaju O, et al. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J Hepatol. 2021;74(1):122–134. doi:10.1016/j.jhep.2020.07.039
   PubMed Web of Science ®Google Scholar
• Han TS, Hur K, Cho HS, Ban HS. Epigenetic associations between lncRNA/circRNA and miRNA in hepatocellular carcinoma. Cancers. 2020;12(9):64.
   Web of Science ®Google Scholar
• Wang X, Yao Z, Fang L. miR-22-3p/PGC1β suppresses breast cancer cell tumorigenesis via PPARγ. PPAR Res. 2021;2021:6661828. doi:10.1155/2021/6661828
   PubMed Web of Science ®Google Scholar
• Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 2022;38(6):613–626. doi:10.1016/j.tig.2022.02.006
   PubMed Web of Science ®Google Scholar
• Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci. 2020;21(5):578.
   PubMed Web of Science ®Google Scholar
• Xie D, Li S, Wu T, Wang X, Fang L. MiR-181c suppresses triple-negative breast cancer tumorigenesis by targeting MAP4K4. Pathol Res Pract. 2022;230:153763. doi:10.1016/j.prp.2022.153763
   PubMed Web of Science ®Google Scholar
• Li N, Zhu L, Zhou H, et al. miRNA-1183-targeted regulation of Bcl-2 contributes to the pathogenesis of rheumatic heart disease. Biosci Rep. 2020;40(11). doi:10.1042/bsr20201573
   Google Scholar
• Wu W, Xi W, Li H, Yang M, Yao X. Circular RNA circ‑ACACA regulates proliferation, migration and glycolysis in non-small-cell lung carcinoma via miR‑1183 and PI3K/PKB pathway. Int J Mol Med. 2020;45(6):1814–1824. doi:10.3892/ijmm.2020.4549
   PubMed Web of Science ®Google Scholar
• Ji C, Zhu L, Fang L. Hsa_circ_0000851 promotes PDK1/p-AKT-mediated cell proliferation and migration by regulating miR-1183 in triple-negative breast cancer. Cell Signal. 2022;101:110494. doi:10.1016/j.cellsig.2022.110494
   PubMed Web of Science ®Google Scholar
• Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Physiol. 2020;598(18):3793–3801. doi:10.1113/jp280389
   PubMed Web of Science ®Google Scholar
• National Research Council Committee for the Update of the Guide for the C, Use of Laboratory A. The National Academies Collection: Reports Funded by National Institutes of Health. Guide for the Care and Use of Laboratory Animals. National Academies Press (US); 2011.
   Google Scholar
• Lee SE, Alcedo KP, Kim HJ, Snider NT. Alternative splicing in hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2020;10(4):699–712. doi:10.1016/j.jcmgh.2020.04.018
   PubMed Web of Science ®Google Scholar
• Zhou HZ, Li F, Cheng ST, et al. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis. Hepatology. 2022;75(4):847–865. doi:10.1002/hep.32195
   PubMed Web of Science ®Google Scholar
• Yu L, Kim J, Jiang L, et al. MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing. Nat Commun. 2020;11(1):708. doi:10.1038/s41467-020-14437-3
   PubMed Web of Science ®Google Scholar
• Anczuków O, Akerman M, Cléry A, et al. SRSF1-regulated alternative splicing in breast cancer. Mol Cell. 2015;60(1):105–117. doi:10.1016/j.molcel.2015.09.005
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang YM, Ma FB, Pan SR, Liu BZ. Long noncoding RNA HOXA11-AS promotes gastric cancer cell proliferation and invasion via SRSF1 and functions as a biomarker in gastric cancer. World j Gastroenterol. 2019;25(22):2763–2775. doi:10.3748/wjg.v25.i22.2763
   PubMed Web of Science ®Google Scholar
• Das T, Lee EY, You HJ, Kim EE, Song EJ. USP15 and USP4 facilitate lung cancer cell proliferation by regulating the alternative splicing of SRSF1. Cell Death Discovery. 2022;8(1):24. doi:10.1038/s41420-022-00820-0
   PubMed Web of Science ®Google Scholar
• Sheng J, Zhao Q, Zhao J, et al. SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance. EBioMedicine. 2018;38:113–126. doi:10.1016/j.ebiom.2018.11.007
   PubMed Web of Science ®Google Scholar
• Wang J, Liu T, Wang M, et al. SRSF1-dependent alternative splicing attenuates BIN1 expression in non-small cell lung cancer. J Cell Biochem. 2020;121(2):946–953. doi:10.1002/jcb.29366
   PubMed Web of Science ®Google Scholar